Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2024 Jul 23;15:1452605. doi: 10.3389/fphar.2024.1452605

Corrigendum: Ginsenoside compound K attenuates ox-LDL-mediated macrophage inflammation and foam cell formation via autophagy induction and modulating NF-kB, p38, and JNK MAPK signaling

Shan Lu 1,2,3,4,5,†, Yun Luo 1,2,3,4,5,†, GuiBo Sun 1,2,3,4,5,*, XiaoBo Sun 1,2,3,4,5,*
PMCID: PMC11301409  PMID: 39108748

In the published article, there was an error in Figure 1 as published. In Figure 1C, the representative pictures in the control and CK groups were the same as in one of our previously published papers. The corrected Figure 1 and its caption appear below.

FIGURE 1.

FIGURE 1

CK inhibited ox-LDL-induced RAW264.7 cells lipid accumulation. RAW264.7 cells were treated with CK at various concentrations for 12 h with or without 80 mg/mL ox-LDL for additional 24 h. (A) The chemical formula for CK. (B) Cell viability was assayed by the MTT assay. (C) Representative images of Oil Red O staining. (D) Oil red O positive area was measured by ImageJ software. All data are shown as mean ± SD from three independent experiments with each performed in triplicate. # p < 0.05, ## p < 0.01 vs. control group; **p < 0.01 vs. ox-LDL-treated group. CK, compound K; ox-LDL, oxidized low-density lipoprotein; MTT, (4, 5-dimethylthiazol-2yl-)-2,5-diphenyl tetrazolium bromide.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES